Exchange: NASDAQ·Updated 03:48 PM EDT
News
all
press releases
SLS, IBRX Stocks Post August Gains: Eli Lilly’s Latest $2.9B Deal Has Retail Traders Bracing For An ‘M&A Rampage’
Retail traders viewed the Merida acquisition as evidence that Big Pharma will pay rich premiums for immune-focused platforms.
Stocktwits
More News
IBRX Stock Heads For Best Week In Over 2 Months After Chairman Soon Shiong’s Cancer Vaccine Trial Milestone Update
Patrick Soon-Shiong said the trial has been fully accrued and passed its one-year mark.
Stocktwits
SLS, IBRX Eye Fresh Oncology Tailwind As Cathie Wood’s ARK Backs Personalized Cancer-Vaccine Future
ARK sees a path toward custom cancer treatments for every patient, though current costs of $200,000-$300,000 remain a major hurdle.
Stocktwits
SLS, IBRX Catch The Eye Of A Major US Pension Fund — And Big Clinical Catalysts Are On The Horizon
Virginia Retirement System disclosed SLS and IBRX stakes worth nearly $909,000 combined.
Stocktwits
IBRX Stock Extends 3-Day Slide — Founder Teases New Trial In ‘Unstoppable’ Cancer-Treatment Push
Soon-Shiong teased a trial pairing Pluvicto’s targeted radiation with an IL-15-based immune treatment.
Stocktwits
SLS, IBRX Stocks In Focus: Analyst Says Moderna-Merck Cancer Vaccine Success ‘Bodes Well’ For Oncology
Moderna soared 177% Wednesday, while Merck gained 13% and the rally spread to BioNTech, Arcturus, Tempus AI and Novavax.
Stocktwits
Moderna Is Now S&P 500’s No. 2 Stock This Year — Wall Street, Jim Cramer And Elon Musk Cheer Cancer Vaccine Breakthrough
The breakthrough sparked a broad biotech rally, lifting Merck, BioNTech, Arcturus, cancer-treatment developers, gene-editing stocks and biotech ETFs.
Stocktwits
Goldman Sachs Builds $75M Bet Across CAPR, SLS And IBRX As Major Catalysts Loom
Goldman increased its stake in Sellas by 5.2% to 585,035 shares, worth $8.64 million.
Stocktwits
SLS And IBRX Eye Green Weekly Close: Vanguard’s Major Stakes In Cancer Drugmakers Steal The Spotlight
Vanguard held SLS and IBRX positions worth a combined $259 million at quarter-end.
Stocktwits
ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that Dr. Jim Yong Kim has joined the company as Vice Chairman. Dr. Kim will serve in a newly created Office of the Executive Chairman, where he will focus on strengthening the company's international and...
Business Wire

Advertisement|Remove ads.